Madrigal Pharma (MDGL) Reports Prelim Q4

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Madrigal Pharma (MDGL) Reports Prelim Q4

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

January 13, 2025 6:45 AM EST

Preliminary fourth-quarter and full-year 2024 Rezdiffra (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 millionAs of year-end 2024, more than 11,800 patients on RezdiffraMadrigal to present at the 43rd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. PST (5:15 p.m. EST) on Wednesday January 15, 2025

CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... More